The acquisition would add a BLA-stage, one-time AAV gene therapy to PTC’s rare disease portfolio, with a rolling US submission expected to complete in the fourth quarter of 2026.

The acquisition would add Nordic Pharma’s €190 million-revenue business and Nordimet rheumatoid arthritis franchise while expanding Alfasigma’s direct commercial presence to 18 European countries and adding platforms in Canada and Japan.

The acquisition would add Caelo’s €40 million-revenue API and excipients business and establish the German company as the anchor of Medios’ planned European network for pharmaceutical compounding ingredients.

The acquisition adds SimoTech’s automation engineering and digital manufacturing expertise to Project Farma’s existing life sciences manufacturing services, creating a broader offering spanning facility strategy through GMP operations.

The acquisition would add a clinical-stage KCNT1 inhibitor for a rare genetic epilepsy with no FDA-approved treatments, while Actio’s remaining programmes will be transferred into a separate privately held company.

The completed transaction combines Kashiv’s biologics R&D and manufacturing capabilities with Amneal’s commercial infrastructure, giving the company end-to-end control across biosimilar development, production and commercialisation.

The proposed acquisition gives Wise Equity control of a specialist oral solid-dose manufacturer with established capabilities in effervescent, soluble, orally disintegrating and sublingual formulations.

The transaction would give Sobi full ownership of a specialist commercialisation platform spanning seven Latin American markets, building on its $105 million investment in Pint Pharma in 2025.

The stock-for-stock acquisition adds a clinical-stage neuroplastogenic pain programme to Ensysce’s pipeline, with concurrent financing expected to fund CY200 through Phase II proof-of-concept data and towards registrational development.

The proposed acquisition would add Xycota’s preclinical CNS pipeline and exosome-based delivery platform to NexTel Medical, including lead programme XYCO-01 for frontotemporal dementia.

The all-stock transaction combines complementary central nervous system portfolios spanning neuroscience and addiction medicine, creating a larger commercial-stage company with a broader product portfolio and pipeline.

The acquisition gives argenx full ownership of FB102, expanding its immunology pipeline with a first-in-class anti-CD122 antibody that has shown early clinical proof of concept in autoimmune disease.

Acquisition gives Lilly late-stage psychedelic pipeline targeting treatment-resistant depression and major psychiatric disorders

Acquisition adds FDA-authorised fibromyalgia therapy and strengthens smartphone-based digital health offering

The agreement expands AstraZeneca’s oncology portfolio with an oral EGFR inhibitor for non-small-cell lung cancer, as Dizal seeks to broaden Zegfrovy’s use into earlier lines of treatment.

The deal gives Vertex access to a commercial acromegaly therapy and a late-stage rare disease pipeline as the company diversifies beyond cystic fibrosis.

The acquisition adds functional electrical stimulation technology to Ottobock’s neuro-orthotics offering, strengthening its position in the growing neurological devices market.

The acquisition adds a novel antibody-drug conjugate payload platform and two preclinical oncology programmes targeting hard-to-treat solid tumours.

The acquisition adds first-in-class BK polyomavirus candidate potravitug as Ipsen continues an aggressive week of dealmaking following its Kartos Therapeutics takeover.

The reverse merger will create Nasdaq-listed Cortigent Holdings, providing Vivani's brain-computer interface business with independent funding to accelerate vision restoration and neurorehabilitation technologies.